kannalife.comHomepage - Kannalife Sciences, Inc. – A Neuropathix Company

Leadership Science Contact Stay Ahead | |Search for: Subsidiary Kannalife Sciences, Inc. Awarded Phase 2 Study Grant from National Institute of Neurological Disorders and Stroke (NINDS) as part of the NIH HEAL Initiative Learn More Kannalife awarded $2.97M grant from NIH 1/4 We’re a Biopharmaceutical Company Engineering Breakthough Therapeutics Targeted for the Treatment of Inflammation, Neurodegeneration, Oxidative Stress and Neuropathic Pain Related Diseases. Visit Website Kannalife Sciences is Targeting Inflammation 2/4 We’re Deploying the Most Creative and Innovative Scientific Minds to Discover and Bring to Market Novel Cannabinoid Therapeutics for Patients with Serious Unmet Medical Needs. Learn More The Science of Kannalife 3/4 CEO Dean Petkanas and Dr. Brenneman talk to NBC’s Dateline about the science of CBD-like therapeutic compounds and their broad potential, including the treatment of pain without opioids. Watch Video Kannalife on Dateline NBC 4/4 Kannalife Sciences, a subsidiary of Neuropathix, Inc., is a biopharmaceutical company focused on the research and development of a pipeline of next generation breakthough therapeutics targeting inflammation to treat patients with significant unmet medical needs. Kannalife, Inc. Appoints Dr. Tage Honoré as Chairman of the Company’s Board of Advisors Kannalife, Inc. Bolsters IP Portfolio with Multiple Patents Issued in 12 Key European Territories Kannalife, Inc. Appoints Terrence O. Tormey to the Company’s Board of Advisors Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine™ Versus CBD Kannalife, Inc. Receives Notice of Allowance from USPTO for Trademark of Atopidine™ Kannalife Bolsters its Global Intellectual Property Portfolio with New Chinese-Issued Patent Kannalife, Inc. Announces Completion of NIH-NIDA Phase 1 Grant and Results from Lewis Katz School of Medicine at Temple University for the Potential Use of KLS-13019 in the Treatment of CIPN Kannalife, Inc. CEO Recaps 2019 Advances and Potential Ahead CBD: Perils, Promise and Development for Neuropathic Pain About Science For almost a decade, Kannalife has been a leader in the research, development and discovery of novel Cannabinoid therapeutic agents for targeted drug candidates to treat Chemotherapy Induced Peripheral Neuropathy (CIPN), Hepatic Encephalopathy (HE), Mild Traumatic Brain Injury (mTBI) and chronic pain management. Kannalife has advanced the development of a proprietary product platform of innovative CBD-like molecules for patients with these diseases and other significant medical needs. We have taken a science based, data-driven, validated approach to the discovery and development of novel and promising therapeutic molecules that are similar to CBD. We are the only company in the cannabinoid therapeutics arena to have licensed the U.S. Government Patent 6,630,507 – Cannabinoids as Antioxidants and Neuroprotectants”. Our pre-clinical research on cannabidiol (CBD) and understanding of certain mechanism of action, its potential and its limitations, has resulted in our own target drug candidate discovery aimed at improving CBD’s pharmacokinetic and pharmacodynamic (PK/PD”) aptitude. In the discovery of KLS-13019 and other patented CBD-like New Chemical Entities (NCE’s), we have made significant improvements in the chemistry efficacy and safety of CBD-like molecules that are up to 200X more potent, 10X more bioavailable, 5X safer and 1000 times more effective than CBD. Get the Latest in Kannalife News Subscribe * indicates required Email Address * Home About Leadership Science Contact Copyright © 2024 Kannalife Sciences, Inc. All rights reserved. COI Policy. Home About Leadership Science...